Significant regulatory and commercial progress for SibnayalTM Control of expenses with a net loss reduced to €12.4 million (vs. €14.8 million) Closing cash position at €12.7 million.
Significant regulatory and commercial progress for SibnayalTM Control of expenses with a net loss reduced to €12.4 million (vs. €14.8 million) Closing cash position at €12.7 million.
Advicenne will receive a transfer price and royalties for an amount markedly higher than 50% of future sales of Sibnayal - Sibnayal will be marketed to one-third of European patients by three members
Corona-Impfung: So wirksam ist die dritte Dosis grazia-magazin.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from grazia-magazin.de Daily Mail and Mail on Sunday newspapers.
Biontech: Der Streit um die dritte Corona-Impfung heise.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from heise.de Daily Mail and Mail on Sunday newspapers.